Alpha 2.0
Login Register
» Authors » Erluo Chen

Erluo Chen

Explore the profile of Erluo Chen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 1893
Followers 0
Related Specialties
Pharmacology
Endocrinology
Cardiology & Vascular Diseases
Top 10 Co-Authors
Anne E de Papp
Richard A Petruschke
Risa Kagan
Darbie Maccubbin
Christine McCrary Sisk
Baek-Yeol Ryoo
Gregory P Geba
Ho Yeong Lim
Joseph Triscari
Thomas Yau
Published In
J Clin Endocrinol Metab
Vasc Health Risk Manag
Curr Med Res Opin
Cancer
Clin Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Kudo M, Lim H, Cheng A, Chao Y, Yau T, Ogasawara S, et al.
Liver Cancer . 2021 Jul; 10(3):275-284. PMID: 34239813
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia...
2.
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
Chao J, Fuchs C, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al.
JAMA Oncol . 2021 Apr; 7(6):895-902. PMID: 33792646
Importance: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. Objective: To evaluate the antitumor activity of pembrolizumab therapy vs...
3.
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Ryoo B, Merle P, Kulkarni A, Cheng A, Bouattour M, Lim H, et al.
Cancer . 2020 Nov; 127(6):865-874. PMID: 33231873
Background: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive...
4.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H, et al.
J Clin Oncol . 2019 Dec; 38(3):193-202. PMID: 31790344
Purpose: Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab...
5.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Dore G, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O, et al.
Ann Intern Med . 2016 Aug; 165(9):625-634. PMID: 27537841
Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Design: Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov:...
6.
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes
Brinton E, Triscari J, Brudi P, Chen E, Johnson-Levonas A, McCrary Sisk C, et al.
Lipids Health Dis . 2016 Jul; 15(1):116. PMID: 27405296
Background: LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM) and/or high TG. These levels...
7.
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
Bays H, Brinton E, Triscari J, Chen E, Maccubbin D, MacLean A, et al.
Vasc Health Risk Manag . 2015 Mar; 11:165-72. PMID: 25750540
Background: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. Objective: Evaluate the lipid-modifying...
8.
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model
Bays H, Chen E, Tomassini J, McPeters G, Polis A, Triscari J
Fundam Clin Pharmacol . 2014 Nov; 29(2):209-18. PMID: 25431239
Co-administration of ezetimibe with atorvastatin is a generally well-tolerated treatment option that reduces LDL-C levels and improves other lipids with greater efficacy than doubling the atorvastatin dose. The objective of...
9.
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
Farnier M, Chen E, Johnson-Levonas A, McCrary Sisk C, Mitchel Y
Vasc Health Risk Manag . 2014 May; 10:279-90. PMID: 24855368
Background: Statins modify correlations between apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) and apoB and non-high-density lipoprotein cholesterol (non-HDL-C); however, it is not known whether niacin-based therapies have similar...
10.
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia
Chen F, Maccubbin D, Yan L, Sirah W, Chen E, McCrary Sisk C, et al.
Int J Cardiol . 2012 Feb; 167(1):225-31. PMID: 22305632
Background: Extended-release niacin/laropiprant (ERN/LRPT) reduces flushing and preserves the lipid-modifying effects of ERN. This study compared the efficacy and safety of ERN/LRPT plus simvastatin (ERN/LRPT+SIMVA) with atorvastatin (ATORVA) in patients...